Inventiva S.A.
IVAHealthcareNASDAQBiotechnology
Scan Results
Daily timeframePart of the healthcare sector, Inventiva S.A. (IVA) is listed under Biotechnology. At a $1.10B market cap, Inventiva S.A. ranks as a small-cap company within healthcare. It develops Lanifibranor, a novel peroxisome proliferator-activated receptor agonist that is in the NATiV3 Phase 3 clinical trial to treat adult patients with MASH; and Odiparcil for the treatment of patients with mucopolysaccharidoses.
Market Cap
$1.10B
Beta
0.92
P/E (TTM)
—
P/E (Fwd)
-5.61
EPS (TTM)
$-2.20
EPS (Fwd)
$-0.83
ROE
—
ROA
-45.1%
Cash
$99.8M
Total Debt
$230.9M
Free CF
-$200.7M
52W Change
-13.6%
Annual Financials
Cash vs Debt
Where IVA stands vs its 150-day and 200-day moving averages
As of the September 2, 2026 close, IVA finished 7.02% below its 150-day moving average ($5.13) and 5.73% below its 200-day moving average ($5.06). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is IVA overbought or oversold?
At the September 2, 2026 close, IVA's RSI(14) was 54.3, in neutral territory (between 30 and 70). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
Inventiva S.A. carries $230.9M in total debt against $99.8M in cash reserves — debt is roughly 2.3x the cash position. Managing this leverage effectively will be important for long-term financial stability. Free cash flow is running at -$200.7M, which bears watching. Negative free cash flow can be acceptable during heavy investment periods but needs to improve over time. Revenue has pulled back from $12.2M (2022) to $4.5M (2025), a 63% decline worth watching.
The company is burning cash at the operating level, which is not unusual for growth-phase companies but adds risk if it persists. These risk factors are not exhaustive — macroeconomic shifts, regulatory changes, and competitive dynamics can all influence Inventiva S.A.'s trajectory.